Myeloma
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Upfront Use of Anti-CD38 Monoclonal Antibodies in NDMM Patients With Renal Failure - A Flatiron Real-World Analysis
FEATURING
Adeel Khan
- 36 views
- February 28, 2025
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Association of Pre-Treatment Biomarkers With Toxicity & Durable Responses to Ide-Cel Therapy for R/R MM
FEATURING
Doris Hansen
- 39 views
- January 21, 2025
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Belamaf Monotherapy in Pts With R/R Light Chain Amyloidosis - Ph2 European Myeloma Network Study
FEATURING
Efstathios Kastritis
- 36 views
- January 13, 2025
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Ph3 ANDROMEDA - Subcutaneous Dara + VCd in Newly Diagnosed Light-Chain Amyloidosis
FEATURING
Efstathios Kastritis
- 49 views
- January 13, 2025
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Highlights in AL Amyloidosis and SMM
FEATURING
Samer Al Hadidi
- 180 views
- January 10, 2025
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Multiple Myeloma Highlights and Clinical Implications
FEATURING
Samer Al Hadidi
- 410 views
- January 10, 2025
- 2
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Myeloma Highlights and Impact on Practice
FEATURING
Hamza Hashmi
- 1,149 views
- January 9, 2025
- 6
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: A High-Fiber Diet in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma
FEATURING
Urvi Shah
- 14 views
- January 9, 2025
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Dara vs. Len Maintenance in NDMM - Interim Results of a Randomized Clinical Trial
FEATURING
Urvi Shah
- 215 views
- January 9, 2025
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Safety and Efficacy of Cilta-Cel vs. Ide-Cel in R/R MM
FEATURING
Doris Hansen
- 46 views
- January 8, 2025
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Transplant in Myeloma - Key Factors in Decision-Making
FEATURING
Aurore Perrot
- 172 views
- January 6, 2025
- 3
2024 ASH Annual Meeting Insights Hub
Talquetamab as a Bridging Therapy to BCMA CAR-T in RRMM
FEATURING
Binod Dhakal
- 141 views
- December 31, 2024
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Secondary Heme Malignancies in Myeloma Post-CAR-T Therapy - Prevalence and Mutational Landscape
FEATURING
Johannes Waldschmidt
- 106 views
- December 31, 2024
- 2
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Efficacy of Anti-BCMA CAR-T in Myeloma Patients Previously Treated With Bispecific Antibodies - Results From a Multi-Center Registry
FEATURING
Johannes Waldschmidt
- 140 views
- December 31, 2024
- 2
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: A Dexamethasone Sparing-Regimen w/ Dara & Len for Frail 1L MM Patients - IFM2017-03 Ph3 Trial
FEATURING
Salomon Manier
- 25 views
- December 24, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Effectiveness of Immunoglobulin Replacement on Hypogammaglobulinemia & Infectious Complications in MM Patients
FEATURING
Elizabeth O'Donnell
- 55 views
- December 23, 2024
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Genomic Determinants of Outcomes in MM With t(11;14) Treated With Venetoclax
FEATURING
Marcella Karddoura
- 14 views
- December 19, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Maintenance With Teclistamab +/- Len or Len Alone in NDMM Post-ASCT - MajesTEC-4/EMN30 Ph3 Safety Run-in
FEATURING
Elena Zamagni
- 25 views
- December 18, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: VRD Consolidation and Len Maintenance in MM - Long-Term EMN02/HOVON95 Ph3 Study Results
FEATURING
Pieter Sonneveld
- 42 views
- December 17, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Ide-Cel in NDMM With Inadequate Response to 1L ASCT - KarMMa-2 Trial Follow-Up
FEATURING
Barry Paul
- 62 views
- December 17, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Optimizing Therapy Duration for Transplant-Ineligible NDMM - Long-Term UK Myeloma XI Data
FEATURING
Charlotte Pawlyn
- 58 views
- December 16, 2024
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Efficacy and Safety of Selinexor, Pomalidomide, and Dexamethasone in RRMM
FEATURING
Muhamed Baljevic
- 75 views
- December 16, 2024
- 2
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Cilta-Cel CAR-T in High-Risk SMM - Results From CAR-PRISM Study
FEATURING
Omar Nadeem
- 45 views
- December 16, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Analyses of MRD Negativity Dynamics in the Phase 3 IMROZ Study - Isa-VRd in Patients With Newly Diagnosed MM
FEATURING
Robert Z. Orlowski
- 120 views
- December 13, 2024
- 3
2024 ASH Annual Meeting Insights Hub
Electronic Patient-Reported Outcome (ePRO) Symptom Monitoring for R/R MM in Community Settings - Focusing on Bispecific Antibody Therapy
FEATURING
Benjamin Derman
- 13 views
- December 13, 2024